Acasti Pharma Set to Participate in Major Investment Conference
Acasti Pharma Inc. (NASDAQ: ACST), a biopharmaceutical company known for its commitment to developing treatments for rare diseases, is gearing up to take part in the H.C. Wainwright 26th Annual Global Investment Conference. This significant event will be held from September 9th to 11th at a prominent venue in New York City.
Engagement with Leadership and Presentation Highlights
Prashant Kohli, Acasti's Chief Executive Officer, will be available for one-on-one meetings on September 9th and 10th, offering investors and stakeholders a chance to engage directly with the company's leadership. During this time, Acasti will also present its latest advancements, including a presentation titled 'Acasti Corporate Presentation,' which will be available on-demand starting September 9th at 7:00 AM EDT.
Spotlight on GTX-104: A Breakthrough Treatment for aSAH
A standout in Acasti's portfolio is GTX-104, an innovative injectable formulation of nimodipine aimed at addressing the urgent medical needs of patients suffering from aneurysmal subarachnoid hemorrhage (aSAH), a serious and potentially life-threatening condition. GTX-104 is set to transform treatment delivery through its unique nanoparticle technology, which allows for effective intravenous infusion, overcoming some limitations of traditional methods.
Advantages of GTX-104 for Patient Care
GTX-104 significantly improves patient care by enabling intravenous administration, which is especially beneficial for unconscious or dysphagic patients who cannot take oral medications. This delivery method minimizes the risk of drug interactions and dosing errors while effectively managing hypotension, a critical aspect of aSAH treatment. Backed by extensive research demonstrating its efficacy and safety, GTX-104 has already been tested in over 150 healthy volunteers.
Acasti's Pediatric Portfolio
In addition to GTX-104, Acasti is also developing GTX-102, a concentrated oral-mucosal spray of betamethasone designed to relieve neurological symptoms in patients diagnosed with Ataxia-Telangiectasia (A-T). Despite the significant potential of GTX-102, Acasti has decided to deprioritize its further development to focus more on advancing GTX-104.
GTX-101: A Non-Narcotic Solution for Pain Management
Acasti has also created GTX-101, a topical formulation of bupivacaine aimed at alleviating pain from postherpetic neuralgia (PHN). While initial results have been encouraging, Acasti is reallocating its resources towards the more urgent development of GTX-104. The advancements showcased at the conference will likely emphasize the potential of both GTX-102 and GTX-101 within the broader landscape of drug development.
About Acasti Pharma
Acasti is committed to developing innovative therapies that meet the unmet needs of patients with rare and orphan diseases. The company’s cutting-edge drug delivery technologies facilitate faster onset of action and improved efficacy, which are essential in critical care settings. Moreover, Acasti has received Orphan Drug Designation from the FDA for its lead assets, ensuring market exclusivity upon approval. This protection is supported by a robust patent portfolio, which includes over 40 granted and pending patents.
As Acasti continues to grow and evolve, staying updated on their developments during the H.C. Wainwright conference will provide valuable insights for both investors and healthcare professionals.
Frequently Asked Questions
What is the primary focus of Acasti Pharma?
Acasti Pharma focuses on developing drugs for rare and orphan diseases, particularly through innovative delivery technologies.
When will Acasti present at the H.C. Wainwright conference?
Acasti's corporate presentation will be available on-demand starting September 9, at 7:00 AM EDT.
What is GTX-104 used for?
GTX-104 is an injectable formulation of nimodipine designed to treat patients suffering from aneurysmal subarachnoid hemorrhage (aSAH).
How does GTX-104 improve treatment delivery?
GTX-104 allows for intravenous delivery, which can eliminate the need for oral administration and reduce dosage errors and drug interactions.
What other products are in Acasti's pipeline?
Acasti is also developing GTX-102, a betamethasone spray for Ataxia-Telangiectasia, and GTX-101, a bupivacaine spray for postherpetic neuralgia.
